343 related articles for article (PubMed ID: 37409360)
21. Development and Validation of a Machine Learning-Based Model Using CT Radiomics for Predicting Immune Checkpoint Inhibitor-related Pneumonitis in Patients With NSCLC Receiving Anti-PD1 Immunotherapy: A Multicenter Retrospective CaseControl Study.
Zhang GY; Du XZ; Xu R; Chen T; Wu Y; Wu XJ; Liu S
Acad Radiol; 2024 May; 31(5):2128-2143. PubMed ID: 37977890
[TBL] [Abstract][Full Text] [Related]
22. Development and Validation of a Novel Survival Prediction Model in Patients With Spinal Metastasis From Non-small Cell Lung Cancer.
Yang M; Xu W; Liu T; Yang X; Wang P; Wu S; Wei H; Zhao J; Yang C; Xiao J
Spine (Phila Pa 1976); 2019 Feb; 44(4):246-257. PubMed ID: 30059487
[TBL] [Abstract][Full Text] [Related]
23. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
[TBL] [Abstract][Full Text] [Related]
24. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
25. Risk analysis of grade ≥ 2 radiation pneumonitis based on radiotherapy timeline in stage III/IV non-small cell lung cancer treated with volumetric modulated arc therapy: a retrospective study.
Yang S; Huang S; Ye X; Xiong K; Zeng B; Shi Y
BMC Pulm Med; 2022 Nov; 22(1):402. PubMed ID: 36344945
[TBL] [Abstract][Full Text] [Related]
26. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
[TBL] [Abstract][Full Text] [Related]
27. [Construction of a nomogram model for predicting 2-year survival rate of small cell lung cancer based on more comprehensive variables].
Wei LJ; Hou Q; Yao NN; Liang Y; Cao X; Sun BC; Li HW; Liu JT; Xu SM; Cao J
Zhonghua Yi Xue Za Zhi; 2022 May; 102(17):1283-1289. PubMed ID: 35488697
[No Abstract] [Full Text] [Related]
28. Development and validation of a nomogram for predicting overall survival of resected N2 non-small cell lung cancer patients undergoing neoadjuvant radiotherapy.
Shi J; Peng B; Wang C; Zhou X; Lu T; Xu R; Chang X; Shen Z; Wang K; Xu C; Zhang L
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11779-11790. PubMed ID: 37407846
[TBL] [Abstract][Full Text] [Related]
29. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
30. Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence.
Xu H; Feng H; Zhang W; Wei F; Zhou L; Liu L; Zhao Y; Lv Y; Shi X; Zhang J; Ren X
Exp Cell Res; 2022 Jul; 416(1):113157. PubMed ID: 35427598
[TBL] [Abstract][Full Text] [Related]
31. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
32. A Comprehensive Nomogram Combining CT Imaging with Clinical Features for Prediction of Lymph Node Metastasis in Stage I-IIIB Non-small Cell Lung Cancer.
Zheng X; Shao J; Zhou L; Wang L; Ge Y; Wang G; Feng F
Ther Innov Regul Sci; 2022 Jan; 56(1):155-167. PubMed ID: 34699046
[TBL] [Abstract][Full Text] [Related]
33. Risk factors and predicting nomogram for the clinical deterioration of non-severe community-acquired pneumonia.
Xu CB; Su SS; Yu J; Lei X; Lin PC; Wu Q; Zhou Y; Li YP
BMC Pulm Med; 2024 Jan; 24(1):57. PubMed ID: 38280994
[TBL] [Abstract][Full Text] [Related]
34. [Prognostic value of skeletal muscle measured by CT at the T4 level in advanced EGFR-positive non-small cell lung cancer patients treated with ecotinib].
Xia H; Tan XY; Lu XT; Wang SF; Cao YQ; Luo P; Song SW; Guo MF; Yang L; Jin Y
Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1590-1600. PubMed ID: 38742346
[No Abstract] [Full Text] [Related]
35. A Risk-Scoring Model for Severe Checkpoint Inhibitor-Related Pneumonitis: A Case-Control Study.
Deng H; Deng J; Lin X; Guan W; Lin Z; Qiu Y; Yang Y; Wu J; Qiu G; Sun N; Zhou M; Deng J; Xie X; Xie Z; Liu M; Qin Y; Zhou Y; Zhou C
Clin Drug Investig; 2023 May; 43(5):347-357. PubMed ID: 37097608
[TBL] [Abstract][Full Text] [Related]
36. [Development and validation of a prognostic model for patients with sepsis in intensive care unit].
Jiang Z; Wang H; Wang S; Guan C; Qu Y
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Aug; 35(8):800-806. PubMed ID: 37593856
[TBL] [Abstract][Full Text] [Related]
37. Checkpoint inhibitor pneumonitis in Chinese lung cancer patients: clinical characteristics and risk factors.
Zhang C; Gao F; Jin S; Gao W; Chen S; Guo R
Ann Palliat Med; 2020 Nov; 9(6):3957-3965. PubMed ID: 33302658
[TBL] [Abstract][Full Text] [Related]
38. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.
Suresh K; Psoter KJ; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; Hales RK; D'Alessio F; Danoff SK; Naidoo J
J Thorac Oncol; 2019 Mar; 14(3):494-502. PubMed ID: 30503891
[TBL] [Abstract][Full Text] [Related]
39. A clinical nomogram based on absolute count of lymphocyte subsets for predicting overall survival in patients with non-small cell lung cancer.
Liu A; Zhang G; Yang Y; Xia Y; Li W; Liu Y; Cui Q; Wang D; Zhao J; Yu J
Int Immunopharmacol; 2023 Jan; 114():109391. PubMed ID: 36508919
[TBL] [Abstract][Full Text] [Related]
40. The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy.
Gao W; Liu Q; Zhou Y; Yang M; Yu Y
Technol Cancer Res Treat; 2023; 22():15330338231206705. PubMed ID: 37927008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
